Search Within

Weining Ma

  1. "Molecular Pharmacology and Chemistry Program Faculty"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (4)
  3. Book Section (1)
Groups
  1. Body Imaging Service (9)
  2. GSK Faculty (9)
  3. Molecular Pharmacology and Chemistry Program Faculty (9)
  4. Radiology, Department of (9)
  5. Sloan Kettering Institute Faculty (9)
  6. Breast Medicine Service (7)

More Groups

People
  1. Shanu Modi (7)
  2. Clifford Hudis (5)
  3. Neal Rosen (5)
  4. David Solit (4)
  5. Larry Norton (4)
  6. Steven Sugarman (3)

More People

Years
  1. 2020 (1)
  2. 2019 (1)
  3. 2013 (1)
  4. 2011 (1)
  5. 2009 (1)
  6. 2008 (2)

More Years

Publications
  1. Cancer Research (2)
  2. Journal of Clinical Oncology (2)
  3. American Journal of Roentgenology (1)
  4. Annals of Oncology (1)
  5. Clinical Cancer Research (1)
  6. JCO Precision Oncology (1)

More Publications

Publishers
  1. American Association for Cancer Research (3)
  2. American Society of Clinical Oncology (3)
  3. American Roentgen Ray Society (1)
  4. Oxford University Press (1)
  5. Wolters Kluwer Health | Lippincott Williams & Wilkins (1)

Results (9)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Measuring tumor epichaperome expression using [(124)I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer
    Journal Article

    Jhaveri, K. L.; dos Anjos, C. H.; Taldone, T.; Wang, R.; Comen, E.; Fornier, M.; Bromberg, J. F.; Ma, W.; Patil, S.; Rodina, A.; more...
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save
  • Tumor epichaperome expression using (124)I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Dunphy, M.; Wang, R.; Comen, E.; Fornier, M.; Moynahan, M. E.; Bromberg, J.; Ma, W.; Patil, S.; Taldone, T.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Diagnostic imaging
    Book Section

    Sala, E.; Lakhman, Y.; Ma, W.; Pannu, H.; Li, D.; Pandit-Taskar, N.; Hricak, H.
    In Barakat, R. R.; Berchuck, A.; Markman, M.; Randall, M. E. (Eds.) Principles and Practice of Gynecologic Oncology. 6th ed (2013)

    Fulltext@MSK | Save
  • HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Journal Article

    Modi, S.; Stopeck, A.; Linden, H.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D'Andrea, G.; Dickler, M.; Moynahan, M. E.; Sugarman, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Imaging appearance of granulomatous disease after intravesical bacille Calmette-GuĂ©rin (BCG) treatment of bladder carcinoma
    Journal Article

    Ma, W.; Kang, S. K.; Hricak, H.; Gerst, S. R.; Zhang, J.
    American Journal of Roentgenology (2009)

    Fulltext@MSK | Save
  • Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Kersey, K.; Johnson, R. G.; Rosen, N.; Hannah, A. L.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Tanespimycin (17-allylamino-17-demethoxy-geldanamycin; 17-AAG) in breast cancer
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Chandarlapaty, S.; Solit, D.; Norton, L.; Rosen, N.; Kersey, K.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I dose-escalation study
    Journal Article

    Modi, S.; Stopeck, A. T.; Gordon, M. S.; Mendelson, D.; Solit, D. B.; Bagatell, R.; Ma, W.; Wheler, J.; Rosen, N.; Norton, L.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase I dose escalating trial of KOS-953 (heat shock protein 90 inhibitor) and trastuzumab (T)
    Meeting Abstract

    Modi, S.; Stopeck, A. T.; Gordon, M. S.; Solit, D.; Bagatell, R.; Ma, W.; Wheler, J.; Cropp, G. F.; Rosen, N.; Johnson, R. G. Jr; more...
    Cancer Research (2006)

    Fulltext@MSK | Save